Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia (AcuPA Study): A Nationwide Survey in Poland
Authors:
- Anna MorawiakAMAnna Morawiak
- Małgorzata Salamonowicz-BodziochMSMałgorzata Salamonowicz-Bodzioch
- Aleksandra KrólakAKAleksandra Królak
- Krzysztof KałwakKKKrzysztof Kałwak
- Joanna Owoc-LempachJOJoanna Owoc-Lempach
- Jerzy KowalczykJKJerzy Kowalczyk
- Joanna ZawitkowskaJoanna Zawitkowska
- Tomasz SzczepańskiTSTomasz Szczepański
- Ninela Irga-JaworskaNINinela Irga-Jaworska
- Elżbieta Adamkiewicz-DrożyńskaEAElżbieta Adamkiewicz-Drożyńska
- Katarzyna AlbrechtKAKatarzyna Albrecht
- Anna Szmydki-BaranASAnna Szmydki-Baran
Open Access
Abstract
Purpose: This study aimed to identify the risk factors for acute pancreatitis (AP) and its impact on outcomes in Polish children treated for ALL. Methods: The study group included 2303 children receiving intensive chemotherapy for ALL. The group was divided into patients with at least one episode of AP and those who did not develop AP after treatment for ALL. Results: The cumulative incidence of AP in the study group was 4.08%. Older age was an independent risk factor for the development of AP (OR = 1.05; 95%CI = 1.006–1.098; p = 0.03). The overall mortality associated with AP was 2.13%. The probabilities of disease-free survival (p-DFS) and event-free survival (p-EFS) in both subgroups were 0.84 vs. 0.86, log-rank p = 0.65 and 0.75 vs. 0.80, log-rank p = 0.12, respectively. A total of 22 out of 94 patients (23.4%) with AP were re-exposed to asparaginase (ASP) during the subsequent treatment phases. Only one patient re-exposed to ASP (4.5%) developed a second episode of AP. There were no significant differences in p-DFS and p-EFS between patients re-exposed and not re-exposed to asparaginase (0.78 vs. 0.86, log-rank p = 0.27 and 0.63 vs. 0.79, log-rank p = 0.09, respectively). Conclusions: The incidence of AP in children with ALL is low and related to patients’ age. The development of AP does not seem to influence p-DFS and p-EFS in children with ALL. Recurrence of AP after re-exposure to asparaginase in patients with ALL and a history of AP is low (4.5%). Re-exposure to asparaginase after the first episode of AP does not improve either p-DFS or p-EFS in children with ALL.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic LeukemiaClinical Lymphoma Myeloma and Leukemia, 2021
- L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis studyCancer Reports, 2021
- Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current PerspectivesPediatric Drugs, 2021
- Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitisPediatric Blood & Cancer, 2020
- Epidemiology of childhood cancerCancer Treatment Reviews, 2010
- Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2009
- Octreotide therapy in asparaginase‐associated pancreatitis in childhood acute lymphoblastic leukemiaPediatric Blood & Cancer, 2008
- Predicting asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2006
- Pegaspargase-induced pancreatitisMedical and Pediatric Oncology, 2000
- Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitisMedical and Pediatric Oncology, 1998